Litt fra CFIDS desember nyhetsbrev
14-15 desember skal Food and Drug Administration (FDA) arrangere en konferanse for Blood Products Advisory Committee slik at de kan vurdere om ME og prostatakreft pasienter bør forbys å gi blod. American Red Cross (den største blodbanken i Amerika) har allerede inngått forbud (det kan du lese om HER og HER) og det blir spennende å se om FDA tar eksempelet til etterfølgelse.
CFIDS gir følgende informasjon i sitt nyhetsbrev:
«The Food and Drug Administration (FDA) regulates the collection of blood and blood components used for transfusion or for the manufacture of pharmaceuticals derived from blood and blood components. FDA has sought the advice of its Blood Products Advisory Committee on the deferral of donors based on a diagnosis of CFS or prostate cancer and testing for the newly identified MLV-related retroviruses (that include XMRV) associated with CFS and prostate cancer that may pose a concern for blood safety. The committee will consider the evidence at its Dec. 14-15 meeting (see «Research Matters» above). The AABB and several other organizations involved in blood collection and transfusion will give statements at the meeting. Last week, the American Red Cross clarified a policy to indefinitely defer individuals reporting a past or present diagnosis of CFS. The policy was fully implemented by Oct. 11, 2010 and data on deferrals (from the American Red Cross and other centers) will be available to the committee. CFIDS Association CEO Kim McCleary will attend the meeting and present a statement that supports the indefinite deferral of individuals with CFS from donating blood, based on the body of evidence of possible risks to recipient and donor amassed over the past 25 years.»
«There will be nine invited presentations on MLVs at the Dec. 14-15, 2010 meeting of the Food and Drug Administration’s Blood Products Advisory Committee, including an update on the blood safety study being coordinated by the National Heart, Lung and Blood Institute. Labs participating in this study experienced delays in testing samples, which held up a progress report expected in November»